A consortium comprising of Investor Growth Capital (IGC), Skandia Investment (SI), the Swedish private equity firms and the CEO of Swedish Orphan International AB (SOI) have agreed to acquire the company. SOI is a Sweden based company with the business concept to develop, register, market and distribute orphan drugs, which are pharmaceuticals used in the treatment of rare disorders, for an undisclosed sum.
Vinge acted for Investor Growth Capital and Skandia Investment.
Ulf Sallnäs (responsible partner)
Helena Dandenell, Kristoffer Persson (associates)
